Tune in for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

America is home to 85 percent of the world’s small, research-intensive biopharma firms. These start-ups are critical to drug development and U.S. competitiveness. Congress should make targeted changes to tax policy to incentivize them and maintain U.S. biopharma leadership.

The technology-transfer regime the United States has implemented over the past four decades, largely as enabled through the Bayh-Dole Act, has been tremendously effective in stimulating innovation, especially in the life sciences. While all such processes should be continuously streamlined or tweaked where improvement is possible, the current system does not need serious modification or reform.

Recognizing the long history of failed efforts to include reasonable pricing clauses in NIH licensing activities, policymakers should reject provisions in the PAHPA Act that would cap the U.S. cost of any products resulting from federal funding “at the lowest price among G7 countries” and do so “at a reasonable price.”

A TRIPS IPR waiver for COVID-19 diagnostics and therapeutics is unnecessary, unwarranted, and even counterproductive—just as it was for COVID-19 vaccines.

Peer-reviewed research finds that pharmaceutical innovation provides direct and indirect benefits for health-care use and disability.

The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.

Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.